Pharmacogenetics: From Bench to Byte-An Update of Guidelines

JJ Swen, Marien Nijenhuis, A den Boer, L Grandia, AH Zee, H Mulder, GAPJM Rongen, Ron van Schaik, T Schalekamp, DJ Touw, J van der Weide, B Wilffert, VHM Deneer, HJ Guchelaar

Research output: Contribution to journalArticleAcademicpeer-review

821 Citations (Scopus)


Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).
Original languageUndefined/Unknown
Pages (from-to)662-673
Number of pages12
JournalClinical Pharmacology & Therapeutics
Issue number5
Publication statusPublished - 2011

Cite this